Compare Duolingo Inc (DUOL) vs HCA Health Inc (HCA) Price & Performance

DUOL trades at $130.9, up 6.79% in 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates at $0.66 versus $0.604 expected, driven by 23% daily active user growth. However, a lower Q3 revenue forecast has tempered optimism. Fundamentals show robust revenue growth to $1.04B in 2025 and a net income margin of 35.87%, though valuation multiples like P/E of 15.47 and P/S of 5.6 suggest premium pricing.

Outlook is mixed: strong user engagement and profitability support upside, but monetization concerns and competitive pressures pose risks. Analysts are cautious with a $121 consensus price target below current levels, highlighting execution challenges in converting growth to sustained revenue.

HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.

The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.